share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Secora Michael
美股SEC公告 ·  08/15 17:27

Moomoo AI 已提取核心訊息

Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock. On August 13 and 14, 2024, Secora exercised options to acquire a total of 78,750 shares at a price of $2.22 per share. Concurrently, he sold 30,000 shares through open market transactions, with sale prices ranging from $6.3455 to $6.3501 per share. The total market value of the disposed shares amounted to $190,434. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals totaled 1,365,343 shares of Class A Common Stock.
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock. On August 13 and 14, 2024, Secora exercised options to acquire a total of 78,750 shares at a price of $2.22 per share. Concurrently, he sold 30,000 shares through open market transactions, with sale prices ranging from $6.3455 to $6.3501 per share. The total market value of the disposed shares amounted to $190,434. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals totaled 1,365,343 shares of Class A Common Stock.
致富金融(臨時代碼)的首席財務官Michael Secora,完成了一系列涉及公司A類普通股的交易。在2024年8月13日和14日,Secora行使了期權,以2.22美元的價格收購了總計78,750股股票。同時,他通過公開市場交易出售了30,000股,銷售價格在每股6.3455美元至6.3501美元之間不等。出售的股票總市值達到了190,434美元。在這些交易完成後,Secora在Recursion Pharmaceuticals擁有1,365,343股A類普通股。
致富金融(臨時代碼)的首席財務官Michael Secora,完成了一系列涉及公司A類普通股的交易。在2024年8月13日和14日,Secora行使了期權,以2.22美元的價格收購了總計78,750股股票。同時,他通過公開市場交易出售了30,000股,銷售價格在每股6.3455美元至6.3501美元之間不等。出售的股票總市值達到了190,434美元。在這些交易完成後,Secora在Recursion Pharmaceuticals擁有1,365,343股A類普通股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息